Recently, the State Drug Administration approved the import of the new drug dacotinib tablets (trade name: Duozerun®) for use in epidermal growth factor receptor (EGFR) exon 19 deletion mutation or exon 21 L858R substitution mutation First-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Dacotinib is an oral, selective, competitive, irreversible, small-molecule inhibitor of human epidermal growth factor receptor (HER, erbB) family receptor tyrosine kinase. Inhibits the tyrosine kinase activity of the EGFR family and exerts an anti-tumor effect. The introduction of dacotinib tablets will provide new treatments for patients with locally advanced or metastatic epidermal growth factor receptor-sensitive mutations in non-small cell lung cancer.
Online
+86-18153515027
BackToTop